J&J to Acquire Ci:z Holdings for Expansion of its Dermatology Portfolio

 J&J to Acquire Ci:z Holdings for Expansion of its Dermatology Portfolio

J&J to Acquire Ci:z Holdings for Expansion of its Dermatology Portfolio

Shots:

  • Ci:z’s acquisition holds two-third of its shares for $52.3/share and ~$2041M as total deal value along with its dermatology products i.e. Dr.Ci:Labo, Labo Labo and Genomer
  • The transaction is expected to enhance and strengthen J&J’s footprints in Japan with its effective dermatology products
  •  On 29 Oct, 2018 J&J will announce its tender offer (acquisition of all remaining shares) for the acquisition, with its expected closure in H1’19

Click here to read full press release/ article | Ref: Johnson & Johnson | Image: Ci:Z-Holdings

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post